Sorrento Therapeutics Boom List

Fortune Bio (Sorrento Manufacturer in China) Posted a video of Covi-Stix being made with CE approval certificate and Respi-Stix listed for sale. http://www.fortunetest.com/
ARD-301 Acquired from Aardvark for Treatment of Long Covid. Ph2 already approved to proceed
STI-6643 Ph1 Trial approved for multiple cancer type treatments “Basket Trial”
Sorrento Therapeutics entered into an Exclusive Licensing Term Sheet with Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome
On February 24, 2021, Sorrento Therapeutics acquire ANP Technologies- PR to follow!
Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, licensed from Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer
Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Haematological Malignancies and Solid Tumours Based on an Exclusive Technology License from the Mayo Clinic- Multiple IND’s in 2021
DARPA sponsoring three new phase 2 trials of COVI-AMG being delivered to 1000 patients. STI2020 is a refined version of 1499 with increased potency and requires smaller dosage.
Feb 4- New COVI-MSC trial starting. Phase 1b tests 100% patients recovered from mechanical ventilation and leaving hospital after a week!!! Phase 2 trials starting to enrol 100 patients
Rheumatoid Arthritis pain relief using Sofusa DoseConnect started Ph1b trial Jan 2021. Drug already approved – this is all about the delivery. Expect rapid results and a massive market.
Abivertinib - Cures Covid at late stages by reducing immune overload (cytokine storm). Stage 2 trials in progress in US and Brazil nearing completion. Over 50% of patients discharged in a placebo controlled test. Very unlikely it is the 50% on placebo so when results unblinded Feb 4- Trials increased to 5 hospitals (Feb 11- 75% enrolled, results due by March 11)- Israel announced they have repurposed a cancer drug with similar positive response.
Jan 2021 BlackRock increased stake in Sorrento massively and now hold 6.7% of all stock!
STI-2020 PR Confirmed it preserves Binding Against UK and SA Covid mutations
Covi-Stix being mass produced. UPS Air crew trialling the product. (CVS Pharmacy rumoured to have ordered 75 million).
RESPI-STIX patent applied for Jan 16 to create combination test for antibody and current viruses including Covid, Flu A and B – Manufacturing at Zhengzhou Fortune Bioscience Co
Looks like we have won a court case with PSS for Cynviloq cancer drug he bought from us. We now have the drug back in our pipeline and expecting $1bn compensation to follow.
Last year we acquired multiple companies. We own 25% of Celulatory who are listing for approx. $2bn due to merger with GX Acquisition Corp
Covi-Drops STI2099 (Refined version of 1499) nasal antibody spray kills all Covid in early stages and can be administered in doctors surgery, maybe at home. PH1b FDA approved March 2
Covi-GUARD STI1499 Antibody which kills 100% of Covid. Rumoured this has been licenced or sold to a big player for $2bn.
11 Covid programs in progress with strong potential- Vaccines removed from pipeline to focus on these, however T-VIVIA-19 could come back to beat mutations if others fail.
Multiple cancer and pain relief plays which triggered BO offers of $7 a year ago before we started developing for Covid.
Yes, we only have one drug approved (ZTildo) but sales are growing massively
We own 10 million shares of Immunity Bio. They are merging with NK in June PSS is chairman making it more likely our Cynviloq case will be settled before then! $$ NK SP Surging
Four analysts have us at $20-35 which is very conservative.
Testing Lab approved in California for Covid (will speed up in house testing and provide source of revenue)
DARPA funding of at least $34m to bring STI 2020 to the end of P2 trials and beyond
CEO gets share options if he maintains SP above $17-130 for six consecutive months
We have been heavily shorted due to a scam by Hindenburg (top 30 most shorted) and now we are poised for a massive short squeeze.
ACEA acquisition due for completion - announcement imminent
SP-102 Ph3 trial results-potentially the first FDA approved epidural steroid product for the treatment of sciatica (massive market) Due by end of March
NDA in China for Abivertinib for NSCLC
Significant recruitment in manufacturing roles over Q4 2020 and Q1 2021